Cargando…
RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway
Congenital dyserythropoietic anemia type II (CDA II) is a hypo-productive anemia defined by ineffective erythropoiesis through maturation arrest of erythroid precursors. CDA II is an autosomal recessive disorder due to loss-of-function mutations in SEC23B. Currently, management of patients with CDA...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432210/ https://www.ncbi.nlm.nih.gov/pubmed/32759740 http://dx.doi.org/10.3390/ijms21155577 |
_version_ | 1783571747219439616 |
---|---|
author | De Rosa, Gianluca Andolfo, Immacolata Marra, Roberta Manna, Francesco Rosato, Barbara Eleni Iolascon, Achille Russo, Roberta |
author_facet | De Rosa, Gianluca Andolfo, Immacolata Marra, Roberta Manna, Francesco Rosato, Barbara Eleni Iolascon, Achille Russo, Roberta |
author_sort | De Rosa, Gianluca |
collection | PubMed |
description | Congenital dyserythropoietic anemia type II (CDA II) is a hypo-productive anemia defined by ineffective erythropoiesis through maturation arrest of erythroid precursors. CDA II is an autosomal recessive disorder due to loss-of-function mutations in SEC23B. Currently, management of patients with CDA II is based on transfusions, splenectomy, or hematopoietic stem-cell transplantation. Several studies have highlighted benefits of ACE-011 (sotatercept) treatment of ineffective erythropoiesis, which acts as a ligand trap against growth differentiation factor (GDF)11. Herein, we show that GDF11 levels are increased in CDA II, which suggests sotatercept as a targeted therapy for treatment of these patients. Treatment of stable clones of SEC23B-silenced erythroleukemia K562 cells with the iron-containing porphyrin hemin plus GDF11 increased expression of pSMAD2 and reduced nuclear localization of the transcription factor GATA1, with subsequent reduced gene expression of erythroid differentiation markers. We demonstrate that treatment of these SEC23B-silenced K562 cells with RAP-011, a “murinized” ortholog of sotatercept, rescues the disease phenotype by restoring gene expression of erythroid markers through inhibition of the phosphorylated SMAD2 pathway. Our data also demonstrate the effect of RAP-011 treatment in reducing the expression of erythroferrone in vitro, thus suggesting a possible beneficial role of the use of sotatercept in the management of iron overload in patients with CDA II. |
format | Online Article Text |
id | pubmed-7432210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74322102020-08-24 RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway De Rosa, Gianluca Andolfo, Immacolata Marra, Roberta Manna, Francesco Rosato, Barbara Eleni Iolascon, Achille Russo, Roberta Int J Mol Sci Article Congenital dyserythropoietic anemia type II (CDA II) is a hypo-productive anemia defined by ineffective erythropoiesis through maturation arrest of erythroid precursors. CDA II is an autosomal recessive disorder due to loss-of-function mutations in SEC23B. Currently, management of patients with CDA II is based on transfusions, splenectomy, or hematopoietic stem-cell transplantation. Several studies have highlighted benefits of ACE-011 (sotatercept) treatment of ineffective erythropoiesis, which acts as a ligand trap against growth differentiation factor (GDF)11. Herein, we show that GDF11 levels are increased in CDA II, which suggests sotatercept as a targeted therapy for treatment of these patients. Treatment of stable clones of SEC23B-silenced erythroleukemia K562 cells with the iron-containing porphyrin hemin plus GDF11 increased expression of pSMAD2 and reduced nuclear localization of the transcription factor GATA1, with subsequent reduced gene expression of erythroid differentiation markers. We demonstrate that treatment of these SEC23B-silenced K562 cells with RAP-011, a “murinized” ortholog of sotatercept, rescues the disease phenotype by restoring gene expression of erythroid markers through inhibition of the phosphorylated SMAD2 pathway. Our data also demonstrate the effect of RAP-011 treatment in reducing the expression of erythroferrone in vitro, thus suggesting a possible beneficial role of the use of sotatercept in the management of iron overload in patients with CDA II. MDPI 2020-08-04 /pmc/articles/PMC7432210/ /pubmed/32759740 http://dx.doi.org/10.3390/ijms21155577 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article De Rosa, Gianluca Andolfo, Immacolata Marra, Roberta Manna, Francesco Rosato, Barbara Eleni Iolascon, Achille Russo, Roberta RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway |
title | RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway |
title_full | RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway |
title_fullStr | RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway |
title_full_unstemmed | RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway |
title_short | RAP-011 Rescues the Disease Phenotype in a Cellular Model of Congenital Dyserythropoietic Anemia Type II by Inhibiting the SMAD2-3 Pathway |
title_sort | rap-011 rescues the disease phenotype in a cellular model of congenital dyserythropoietic anemia type ii by inhibiting the smad2-3 pathway |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432210/ https://www.ncbi.nlm.nih.gov/pubmed/32759740 http://dx.doi.org/10.3390/ijms21155577 |
work_keys_str_mv | AT derosagianluca rap011rescuesthediseasephenotypeinacellularmodelofcongenitaldyserythropoieticanemiatypeiibyinhibitingthesmad23pathway AT andolfoimmacolata rap011rescuesthediseasephenotypeinacellularmodelofcongenitaldyserythropoieticanemiatypeiibyinhibitingthesmad23pathway AT marraroberta rap011rescuesthediseasephenotypeinacellularmodelofcongenitaldyserythropoieticanemiatypeiibyinhibitingthesmad23pathway AT mannafrancesco rap011rescuesthediseasephenotypeinacellularmodelofcongenitaldyserythropoieticanemiatypeiibyinhibitingthesmad23pathway AT rosatobarbaraeleni rap011rescuesthediseasephenotypeinacellularmodelofcongenitaldyserythropoieticanemiatypeiibyinhibitingthesmad23pathway AT iolasconachille rap011rescuesthediseasephenotypeinacellularmodelofcongenitaldyserythropoieticanemiatypeiibyinhibitingthesmad23pathway AT russoroberta rap011rescuesthediseasephenotypeinacellularmodelofcongenitaldyserythropoieticanemiatypeiibyinhibitingthesmad23pathway |